Your browser doesn't support javascript.
loading
Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial.
Schneider, Simon R; Mayer, Laura C; Lichtblau, Mona; Berlier, Charlotte; Schwarz, Esther I; Saxer, Stéphanie; Tan, Lu; Furian, Michael; Bloch, Konrad E; Ulrich, Silvia.
Afiliação
  • Schneider SR; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Mayer LC; Dept of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
  • Lichtblau M; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Berlier C; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Schwarz EI; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Saxer S; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Tan L; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Furian M; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Bloch KE; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Ulrich S; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
ERJ Open Res ; 7(4)2021 Oct.
Article em En | MEDLINE | ID: mdl-34651040
ABSTRACT
QUESTION ADDRESSED BY THE STUDY To investigate exercise performance and hypoxia-related health effects in patients with pulmonary hypertension (PH) during a high-altitude sojourn. PATIENTS AND

METHODS:

In a randomised crossover trial in stable (same therapy for >4 weeks) patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) with resting arterial oxygen tension (P aO2 ) ≥7.3 kPa, we compared symptom-limited constant work-rate exercise test (CWRET) cycling time during a day-trip to 2500 m versus 470 m. Further outcomes were symptoms, oxygenation and echocardiography. For safety, patients with sustained hypoxaemia at altitude (peripheral oxygen saturation <80% for >30 min or <75% for >15 min) received oxygen therapy.

RESULTS:

28 PAH/CTEPH patients (n=15/n=13); 13 females; mean±sd age 63±15 years were included. After >3 h at 2500 m versus 470 m, CWRET-time was reduced to 17±11 versus 24±9 min (mean difference -6, 95% CI -10 to -3), corresponding to -27.6% (-41.1 to -14.1; p<0.001), but similar Borg dyspnoea scale. At altitude, P aO2 was significantly lower (7.3±0.8 versus 10.4±1.5 kPa; mean difference -3.2 kPa, 95% CI -3.6 to -2.8 kPa), whereas heart rate and tricuspid regurgitation pressure gradient (TRPG) were higher (86±18 versus 71±16 beats·min-1, mean difference 15 beats·min-1, 95% CI 7 to 23 beats·min-1) and 56±25 versus 40±15 mmHg (mean difference 17 mmHg, 95% CI 9 to 24 mmHg), respectively, and remained so until end-exercise (all p<0.001). The TRPG/cardiac output slope during exercise was similar at both altitudes. Overall, three (11%) out of 28 patients received oxygen at 2500 m due to hypoxaemia.

CONCLUSION:

This randomised crossover study showed that the majority of PH patients tolerate a day-trip to 2500 m well. At high versus low altitude, the mean exercise time was reduced, albeit with a high interindividual variability, and pulmonary artery pressure at rest and during exercise increased, but pressure-flow slope and dyspnoea were unchanged.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article